Moa Life Plus

Moa Life Plus has a market price of 859 KRW per share, with a market capitalization of 34,272,732,472 KRW. The company's price-to-book ratio is 1.12, and its price-to-tangible-book ratio is also 1.12, indicating that the market value is slightly above the book value of the company's tangible assets. The enterprise value to EBITDA ratio is negative at -6.63, reflecting the company's current unprofitability, while the enterprise value to revenue ratio is 3.65, suggesting a moderate valuation relative to its revenue. The company's profitability is weak, with a return on equity of -42.77% and a return on assets of -30.68%, both significantly below the industry norms for pharmaceutical companies. The gross profit margin is 16.52%, and the operating margin is -55.09%, indicating substantial operational inefficiencies and cost overruns. The debt-to-equity ratio is 0.22, suggesting a relatively low level of leverage, and the current ratio is 2.31, indicating that the company has sufficient short-term assets to cover its short-term liabilities. Moa Life Plus generates revenue from biotechnology, biopharmaceuticals, health functional foods, and functional cosmetics, as well as the distribution of pharmaceuticals and medical supplies. The company's revenue concentration is not disclosed, but the lack of segment-specific data suggests a need for further transparency in its financial reporting. The company's operating cash flow is negative at -5,970,131,670 KRW, and its free cash flow is also negative at -11,641,754,920 KRW, indicating a lack of cash generation from operations. The company's growth trajectory is uncertain, with a net income of -13,071,372,710 KRW and an operating income of -6,178,131,990 KRW. The capital expenditure is -213,223,040 KRW, suggesting a reduction in investment in long-term assets. The company's revenue for the latest period is 11,216,210,530 KRW, which is lower than the analyst estimate of 80,437,360,000 KRW, indicating a significant shortfall in revenue performance. The company faces medium liquidity risk, as indicated by the negative net cash position after subtracting total debt. The dilution risk is low, but the company's negative operating and free cash flows suggest a potential need for additional financing, which could lead to share dilution in the future. The company's recent financial performance and operational inefficiencies highlight the need for strategic improvements to enhance profitability and cash flow generation. Recent events and filings indicate that the company is engaged in the development of cervical cancer treatment and anticancer drugs. The company's focus on biotechnology and biopharmaceuticals suggests a long-term strategy to expand its product portfolio and market presence. However, the lack of recent positive financial results and the negative cash flows indicate a need for immediate operational and financial improvements.